Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 213

Sort by

Sort Order Select

Journal Articles

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/ PD-L1/PD-L2 alterations

Marthe Minderman, Avital Amir, Willem Kraan, Esther J. M. Schilder-Tol, Monique E. C. M. Oud, Cornelis G. Scheepstra, Arnold L. Noorduyn, Philip M. Kluin, Marie José Kersten, Marcel Spaargaren, Steven T. Pals

Blood (2021) 138 (13): 1194–1197.

https://doi.org/10.1182/blood.2021011366

Published: 2021

Includes: Supplemental data

Journal Articles

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Blood (2021) 137 (11): 1491–1502.

https://doi.org/10.1182/blood.2020007245

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

Alexandre S. Cristino, Jamie Nourse, Rachael A. West, Muhammed Bilal Sabdia, Soi C. Law, Jay Gunawardana, Frank Vari, Sally Mujaj, Gayathri Thillaiyampalam, Cameron Snell, Madeline Gough, Colm Keane, Maher K. Gandhi

Blood (2019) 134 (25): 2261–2270.

https://doi.org/10.1182/blood.2019000889

Published: 2019

Includes: Supplemental data

Journal Articles

A MYC Driven and Metabolite Executed Axis Controls the Subcellular Localization and Activity of TET DNA Hydroxylases and RNA Demethylases in B Cell Lymphomas

Zhijun Qiu, PhD, An-Ping Lin, MD, Shoulei Jiang, PhD, Binu Sasi, PhD, Patricia Dahia, MD PhD, Siyuan Zheng, PhD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 114.

https://doi.org/10.1182/blood-2019-123101

Published: 2019

Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 5238.

https://doi.org/10.1182/blood-2019-131941

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): SCI-8.

https://doi.org/10.1182/blood-2019-121284

Published: 2019

Journal Articles

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Hsu-Chih Chien, PhD MSc, Vikas Patil, MS, Kelli M Rasmussen, MS, Christina Yong, MA, Juliana M L Biondo, MD, Mary Halloran, PharmD, BCPS, Sheila Shapouri, PharmD, MS, Mei Wu, PharmD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 4309.

https://doi.org/10.1182/blood-2019-128645

Published: 2019

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

Ahmad S Halwani, MD, Hsu-Chih Chien, PhD MSc, Deborah Kay Morreall, BS, Vikas Patil, MS, Kelli M Rasmussen, MS, Catherine Li, PhD, Zachary R Burningham, PhD, Anthony S Masaquel, PhD MPH, Mary Halloran, PharmD, BCPS, Elisha Delong-Sieg, PharmD, Mathias Schulz, MD MBA, Jia Li, PhD, Brian C Sauer, PhD

Blood (2019) 134 (Supplement_1): 1622.

https://doi.org/10.1182/blood-2019-127719

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

Immunosuppressive Diversity of Umbilical Cord-Derived Mesenchymal Stromal Cells

Tokiko Nagamura-Inoue, MD PhD, Atsuko Takahashi, MT., Yuki Yamamoto, MT, Akiko Hori, Yuta Miharu, MT, Kazuo Ogami, MT, Miwako Narita, MD PhD, Fumitaka Nagamura, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 3584.

https://doi.org/10.1182/blood-2019-128627

Published: 2019

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

PD-L1 Expression in Patients with Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Its Correlation with Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1)

Inju Cho, MD PhD, Seok Jin Kim, MD PhD, Hansang Lee, MD, Young Hyeh Ko, MD

Blood (2019) 134 (Supplement_1): 1601.

https://doi.org/10.1182/blood-2019-123311

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1428.

https://doi.org/10.1182/blood-2019-128601

Published: 2019

Journal Articles

Tissue-Resident PSGL1 lo CD4 + T Cells Interact with B Cells Via PD-1 and PD-L2 in Gvhd Target Tissues to Augment Autoimmune-like Chronic Gvhd

Xiaohui Kong, PhD, Deye Zeng, MD, Xiwei Wu, PhD, Shijie Yang, PhD, Bixin Wang, Qingxiao Song, MD PhD, Yongping Zhu, Martha Salas, Hanjun Qin, Ubaydah Nasri, Ryotaro Nakamura, MD, Paul J Martin, MD, Aimin Huang, Defu Zeng, MD PhD

Blood (2019) 134 (Supplement_1): 5607.

https://doi.org/10.1182/blood-2019-126315

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

NARROW

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/ PD-L1/PD-L2 alterations

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Immune escape mechanisms for TCRLBCL

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

A MYC Driven and Metabolite Executed Axis Controls the Subcellular Localization and Activity of TET DNA Hydroxylases and RNA Demethylases in B Cell Lymphomas

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Discontinuation Patterns in Patients Receiving Novel Oral Agents for Chronic Lymphocytic Leukemia in the Veterans Health Administration

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Immunosuppressive Diversity of Umbilical Cord-Derived Mesenchymal Stromal Cells

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

PD-L1 Expression in Patients with Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Its Correlation with Serum Levels of Soluble Programmed Death-Ligand 1 (sPD-L1)

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Tissue-Resident PSGL1 lo CD4 + T Cells Interact with B Cells Via PD-1 and PD-L2 in Gvhd Target Tissues to Augment Autoimmune-like Chronic Gvhd

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only